ORIC is advancing a diverse pipeline of clinical and discovery stage therapies designed to counter resistance mechanisms in cancer by leveraging expertise within three specific areas: hormone-dependent cancers, precision oncology and key tumor dependencies. Lead candidates include enozertinib (ORIC-114) and rinzimetostat (ORIC-944) in clinical development.
Cyborg Score Rationale
ORIC is a clinical-stage biotech with a focused pipeline addressing validated cancer resistance mechanisms, but faces typical clinical-stage risks including execution risk on pipeline advancement and cash runway. The company's cash from a January 2024 financing was expected to fund operations into late 2026.
Top Insights
Pipeline addresses three strategic oncology areas: hormone-dependent cancers, precision oncology, and key tumor dependencies.
Lead program enozertinib (ORIC-114) is a brain penetrant EGFR/HER2 exon 20 inhibitor in Phase 1b development.
Stock has experienced substantial shareholder dilution in the past year with high volatility.
Raised $125 million in private placement financing in January 2024 from top-tier healthcare investors including Viking Global, Frazier Life Sciences, and NEA.
Named Competitors
Tagrisso — EGFR mutation-targeted lung cancer therapy
Exkivity — EGFR exon 20 insertion inhibitor for lung cancer
Loxo Oncology programs — Precision oncology targeting TRK and other mutations
Recent Developments
(May 2026) Positive analyst sentiment with Buy ratings from Piper Sandler, Guggenheim, and Wells Fargo
(January 2024) Closed $125 million Series C private placement financing
(Q1 2026) Presented preclinical data on rinzimetostat at American Association of Cancer Research conference
Open the full interactive ORIC Pharmaceuticals, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.